anti-HLA-A2 TCR T-cell therapy (Juno)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-HLA-A2 TCR T-cell therapy (Juno)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators

TargetsHLA Class I Histocompatibility Antigen, A-2 alpha Chain

Therapy Area/IndicationsLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesJuno Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesJuno Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLeukemia

Other Information

ATC CodeN/A